---
document_datetime: 2025-12-02 05:14:05
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/hemgenix.html
document_name: hemgenix.html
version: success
processing_time: 0.1080761
conversion_datetime: 2025-12-24 19:44:50.332257
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Hemgenix

[RSS](/en/individual-human-medicine.xml/67647)

##### Authorised

This medicine is authorised for use in the European Union

etranacogene dezaparvovec Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Hemgenix](#news-on)
- [More information on Hemgenix](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Hemgenix is a medicine used to treat adults with severe and moderately severe haemophilia B, an inherited bleeding disorder caused by the lack of factor IX (a protein needed to produce blood clots to stop bleeding). It is used in adults who have not developed inhibitors (proteins made by the body's natural defenses) against factor IX.

Haemophilia B is rare, and Hemgenix was designated an 'orphan medicine' (a medicine used in rare diseases) on 21 March 2018. Further information on the orphan designation can be found here: [EU/3/18/1999](/en/medicines/human/orphan-designations/eu-3-18-1999)

Hemgenix contains the active substance etranacogene dezaparvovec and is a type of advanced therapy medicine called a 'gene therapy product'. This is a type of medicine that works by delivering genes into the body.

Expand section

Collapse section

## How is Hemgenix used?

The medicine can only be obtained with a prescription. Treatment must be started under the supervision of a doctor experienced in the treatment of haemophilia and/or bleeding disorders, in a facility equipped to promptly treat infusion-related reactions.

Hemgenix is given once, as a single infusion (drip) into a vein lasting one to two hours. The dose depends on the patient's body weight.

Before receiving the infusion, the patient will have a number of tests, including tests to check their liver health and if they have factor IX inhibitors. As it will be several weeks before Hemgenix shows any effects, patients will be monitored closely for at least 3 months after the infusion to decide if they need additional treatment with factor IX replacement therapy.

For more information about using Hemgenix, see the package leaflet or contact your doctor or pharmacist.

## How does Hemgenix work?

Patients with haemophilia B have mutations (changes) in a gene which the body needs to make the clotting protein Factor IX, resulting in either a partial or complete lack of its activity.

The active substance in Hemgenix, etranacogene dezaparvovec, is based on a virus that contains copies of the gene responsible for producing factor IX. When given to the patient, the virus will carry the factor IX gene to the liver cells, enabling them to produce the missing factor IX and thereby limit bleeding episodes.

The type of virus used in this medicine (adeno-associated virus) does not cause disease in humans.

## What benefits of Hemgenix have been shown in studies?

A study in 54 adult male patients with severe or moderately severe haemophilia B found that Hemgenix was more effective at reducing bleeding events than factor IX replacement therapy. The study compared the number of bleeding episodes patients had with factor IX replacement therapy during a 6-month period before receiving Hemgenix with the number experienced over a 1 year period after achieving stable factor IX levels with Hemgenix. Data from the study showed that Hemgenix reduced the yearly bleeding rate from 4.2 to 1.5 bleeds per year. The study also found that Hemgenix was effective at increasing factor IX levels, with 96% of patients (52 out of 54) no longer needing factor IX replacement therapy for up to 2 years after the infusion.

## What are the risks associated with Hemgenix?

The most common side effects with Hemgenix (which may affect more than 1 in 10 people) are headache, increased levels of certain liver enzymes and flu-like symptoms.

For the full list of side effects of Hemgenix, see the package leaflet.

Hemgenix must not be given to people who are hypersensitive (allergic) to any of its ingredients, who have an active or chronic (long-term) infection that is not controlled by medicines, or who have advanced liver fibrosis or liver cirrhosis (scarring of the liver).

## Why is Hemgenix authorised in the EU?

At the time of approval, patients with severe haemophilia B required lifelong treatment with factor IX replacement therapy. Hemgenix, given as a single infusion, was effective at preventing bleeding over a period of at least 2 years, thus enabling patients to discontinue treatment with factor IX replacement therapy, which reduces the burden caused by treating the disease. There are some uncertainties about how long the benefits of Hemgenix last, given that the main study evaluated the response in a small number of patients for up to 2 years. Although the long-term safety data were limited, the safety profile was considered acceptable.

Hemgenix has been given 'conditional authorisation'. This means that the European Medicines Agency decided that the benefits of Hemgenix are greater than its risks, but the company will have to provide additional evidence after authorisation.

Conditional authorisation is granted on the basis of less comprehensive data than are normally required. It is granted for medicines that fulfil an unmet medical need to treat serious diseases and when the benefits of having them available earlier outweigh any risks associated with using the medicines while waiting for further evidence. Every year, the European Medicines Agency will review any new information that becomes available until data become comprehensive and this overview will be updated as necessary.

## What information is still awaited for Hemgenix?

Since Hemgenix has been given conditional authorisation, the company that markets this medicine will provide additional data from ongoing studies on the long-term safety and effectiveness of the medicine, including how long the response lasts, in patients with severe to moderately severe haemophilia B. The company will also provide data from a registry of patients treated with Hemgenix to study its long-term safety and effectiveness.

## What measures are being taken to ensure the safe and effective use of Hemgenix?

The company that markets Hemgenix will provide educational materials to patients or their carers and to healthcare professionals, with information on the benefits, risks and uncertainties about the long term effects and safety of the medicine. Patients must also be given a patient card to inform healthcare professionals that they have been treated with Hemgenix.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Hemgenix have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Hemgenix are continuously monitored. Suspected side effects reported with Hemgenix are carefully evaluated and any necessary action taken to protect patients.

## Other information about Hemgenix

Hemgenix received a conditional marketing authorisation valid throughout the EU on 20 February 2023.

Hemgenix : EPAR - Medicine overview

Reference Number: EMA/45357/2023

English (EN) (119.47 KB - PDF)

**First published:** 28/02/2023

[View](/en/documents/overview/hemgenix-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-872)

български (BG) (138.29 KB - PDF)

**First published:**

28/02/2023

[View](/bg/documents/overview/hemgenix-epar-medicine-overview_bg.pdf)

español (ES) (110.29 KB - PDF)

**First published:**

28/02/2023

[View](/es/documents/overview/hemgenix-epar-medicine-overview_es.pdf)

čeština (CS) (135.8 KB - PDF)

**First published:**

28/02/2023

[View](/cs/documents/overview/hemgenix-epar-medicine-overview_cs.pdf)

dansk (DA) (111.03 KB - PDF)

**First published:**

28/02/2023

[View](/da/documents/overview/hemgenix-epar-medicine-overview_da.pdf)

Deutsch (DE) (115.11 KB - PDF)

**First published:**

28/02/2023

[View](/de/documents/overview/hemgenix-epar-medicine-overview_de.pdf)

eesti keel (ET) (105.62 KB - PDF)

**First published:**

28/02/2023

[View](/et/documents/overview/hemgenix-epar-medicine-overview_et.pdf)

ελληνικά (EL) (138.75 KB - PDF)

**First published:**

28/02/2023

[View](/el/documents/overview/hemgenix-epar-medicine-overview_el.pdf)

français (FR) (112.03 KB - PDF)

**First published:**

28/02/2023

[View](/fr/documents/overview/hemgenix-epar-medicine-overview_fr.pdf)

hrvatski (HR) (134.02 KB - PDF)

**First published:**

28/02/2023

[View](/hr/documents/overview/hemgenix-epar-medicine-overview_hr.pdf)

italiano (IT) (110.05 KB - PDF)

**First published:**

28/02/2023

[View](/it/documents/overview/hemgenix-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (148.82 KB - PDF)

**First published:**

28/02/2023

[View](/lv/documents/overview/hemgenix-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (133.7 KB - PDF)

**First published:**

28/02/2023

[View](/lt/documents/overview/hemgenix-epar-medicine-overview_lt.pdf)

magyar (HU) (134.36 KB - PDF)

**First published:**

28/02/2023

[View](/hu/documents/overview/hemgenix-epar-medicine-overview_hu.pdf)

Malti (MT) (135.75 KB - PDF)

**First published:**

28/02/2023

[View](/mt/documents/overview/hemgenix-epar-medicine-overview_mt.pdf)

Nederlands (NL) (111.67 KB - PDF)

**First published:**

28/02/2023

[View](/nl/documents/overview/hemgenix-epar-medicine-overview_nl.pdf)

polski (PL) (138.7 KB - PDF)

**First published:**

28/02/2023

[View](/pl/documents/overview/hemgenix-epar-medicine-overview_pl.pdf)

português (PT) (111.42 KB - PDF)

**First published:**

28/02/2023

[View](/pt/documents/overview/hemgenix-epar-medicine-overview_pt.pdf)

română (RO) (131.99 KB - PDF)

**First published:**

28/02/2023

[View](/ro/documents/overview/hemgenix-epar-medicine-overview_ro.pdf)

slovenčina (SK) (133.35 KB - PDF)

**First published:**

28/02/2023

[View](/sk/documents/overview/hemgenix-epar-medicine-overview_sk.pdf)

slovenščina (SL) (133.91 KB - PDF)

**First published:**

28/02/2023

[View](/sl/documents/overview/hemgenix-epar-medicine-overview_sl.pdf)

Suomi (FI) (108.28 KB - PDF)

**First published:**

28/02/2023

[View](/fi/documents/overview/hemgenix-epar-medicine-overview_fi.pdf)

svenska (SV) (108.99 KB - PDF)

**First published:**

28/02/2023

[View](/sv/documents/overview/hemgenix-epar-medicine-overview_sv.pdf)

Hemgenix : EPAR - Risk Management Plan

English (EN) (2.24 MB - PDF)

**First published:** 28/02/2023

[View](/en/documents/rmp/hemgenix-epar-risk-management-plan_en.pdf)

## Product information

Hemgenix : EPAR - Product information

English (EN) (582.93 KB - PDF)

**First published:** 28/02/2023

**Last updated:** 15/01/2025

[View](/en/documents/product-information/hemgenix-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-941)

български (BG) (697.07 KB - PDF)

**First published:**

28/02/2023

**Last updated:**

15/01/2025

[View](/bg/documents/product-information/hemgenix-epar-product-information_bg.pdf)

español (ES) (594.07 KB - PDF)

**First published:**

28/02/2023

**Last updated:**

15/01/2025

[View](/es/documents/product-information/hemgenix-epar-product-information_es.pdf)

čeština (CS) (779.55 KB - PDF)

**First published:**

28/02/2023

**Last updated:**

15/01/2025

[View](/cs/documents/product-information/hemgenix-epar-product-information_cs.pdf)

dansk (DA) (589.38 KB - PDF)

**First published:**

28/02/2023

**Last updated:**

15/01/2025

[View](/da/documents/product-information/hemgenix-epar-product-information_da.pdf)

Deutsch (DE) (637.04 KB - PDF)

**First published:**

28/02/2023

**Last updated:**

15/01/2025

[View](/de/documents/product-information/hemgenix-epar-product-information_de.pdf)

eesti keel (ET) (595.95 KB - PDF)

**First published:**

28/02/2023

**Last updated:**

15/01/2025

[View](/et/documents/product-information/hemgenix-epar-product-information_et.pdf)

ελληνικά (EL) (677.98 KB - PDF)

**First published:**

28/02/2023

**Last updated:**

15/01/2025

[View](/el/documents/product-information/hemgenix-epar-product-information_el.pdf)

français (FR) (607.37 KB - PDF)

**First published:**

28/02/2023

**Last updated:**

15/01/2025

[View](/fr/documents/product-information/hemgenix-epar-product-information_fr.pdf)

hrvatski (HR) (618.2 KB - PDF)

**First published:**

28/02/2023

**Last updated:**

15/01/2025

[View](/hr/documents/product-information/hemgenix-epar-product-information_hr.pdf)

íslenska (IS) (598.48 KB - PDF)

**First published:**

28/02/2023

**Last updated:**

15/01/2025

[View](/is/documents/product-information/hemgenix-epar-product-information_is.pdf)

italiano (IT) (685.53 KB - PDF)

**First published:**

28/02/2023

**Last updated:**

15/01/2025

[View](/it/documents/product-information/hemgenix-epar-product-information_it.pdf)

latviešu valoda (LV) (615.35 KB - PDF)

**First published:**

28/02/2023

**Last updated:**

15/01/2025

[View](/lv/documents/product-information/hemgenix-epar-product-information_lv.pdf)

lietuvių kalba (LT) (620.61 KB - PDF)

**First published:**

28/02/2023

**Last updated:**

15/01/2025

[View](/lt/documents/product-information/hemgenix-epar-product-information_lt.pdf)

magyar (HU) (625.27 KB - PDF)

**First published:**

28/02/2023

**Last updated:**

15/01/2025

[View](/hu/documents/product-information/hemgenix-epar-product-information_hu.pdf)

Malti (MT) (680.28 KB - PDF)

**First published:**

28/02/2023

**Last updated:**

15/01/2025

[View](/mt/documents/product-information/hemgenix-epar-product-information_mt.pdf)

Nederlands (NL) (580.76 KB - PDF)

**First published:**

28/02/2023

**Last updated:**

15/01/2025

[View](/nl/documents/product-information/hemgenix-epar-product-information_nl.pdf)

norsk (NO) (569.36 KB - PDF)

**First published:**

28/02/2023

**Last updated:**

15/01/2025

[View](/no/documents/product-information/hemgenix-epar-product-information_no.pdf)

polski (PL) (640.98 KB - PDF)

**First published:**

28/02/2023

**Last updated:**

15/01/2025

[View](/pl/documents/product-information/hemgenix-epar-product-information_pl.pdf)

português (PT) (583.17 KB - PDF)

**First published:**

28/02/2023

**Last updated:**

15/01/2025

[View](/pt/documents/product-information/hemgenix-epar-product-information_pt.pdf)

română (RO) (695.06 KB - PDF)

**First published:**

28/02/2023

**Last updated:**

15/01/2025

[View](/ro/documents/product-information/hemgenix-epar-product-information_ro.pdf)

slovenčina (SK) (723.96 KB - PDF)

**First published:**

28/02/2023

**Last updated:**

15/01/2025

[View](/sk/documents/product-information/hemgenix-epar-product-information_sk.pdf)

slovenščina (SL) (676.8 KB - PDF)

**First published:**

28/02/2023

**Last updated:**

15/01/2025

[View](/sl/documents/product-information/hemgenix-epar-product-information_sl.pdf)

Suomi (FI) (598.31 KB - PDF)

**First published:**

28/02/2023

**Last updated:**

15/01/2025

[View](/fi/documents/product-information/hemgenix-epar-product-information_fi.pdf)

svenska (SV) (622.37 KB - PDF)

**First published:**

28/02/2023

**Last updated:**

15/01/2025

[View](/sv/documents/product-information/hemgenix-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0018 12/12/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Hemgenix : EPAR - All authorised presentations

Adopted

English (EN) (38.88 KB - PDF)

**First published:** 28/02/2023

[View](/en/documents/all-authorised-presentations/hemgenix-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-922)

български (BG) (47.95 KB - PDF)

**First published:**

28/02/2023

[View](/bg/documents/all-authorised-presentations/hemgenix-epar-all-authorised-presentations_bg.pdf)

español (ES) (62.68 KB - PDF)

**First published:**

28/02/2023

[View](/es/documents/all-authorised-presentations/hemgenix-epar-all-authorised-presentations_es.pdf)

čeština (CS) (48.85 KB - PDF)

**First published:**

28/02/2023

[View](/cs/documents/all-authorised-presentations/hemgenix-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (37.34 KB - PDF)

**First published:**

28/02/2023

[View](/da/documents/all-authorised-presentations/hemgenix-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (41.4 KB - PDF)

**First published:**

28/02/2023

[View](/de/documents/all-authorised-presentations/hemgenix-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (38.13 KB - PDF)

**First published:**

28/02/2023

[View](/et/documents/all-authorised-presentations/hemgenix-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (54.2 KB - PDF)

**First published:**

28/02/2023

[View](/el/documents/all-authorised-presentations/hemgenix-epar-all-authorised-presentations_el.pdf)

français (FR) (37.5 KB - PDF)

**First published:**

28/02/2023

[View](/fr/documents/all-authorised-presentations/hemgenix-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (77.35 KB - PDF)

**First published:**

28/02/2023

[View](/hr/documents/all-authorised-presentations/hemgenix-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (40.03 KB - PDF)

**First published:**

28/02/2023

[View](/is/documents/all-authorised-presentations/hemgenix-epar-all-authorised-presentations_is.pdf)

italiano (IT) (38.49 KB - PDF)

**First published:**

28/02/2023

[View](/it/documents/all-authorised-presentations/hemgenix-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (54.33 KB - PDF)

**First published:**

28/02/2023

[View](/lv/documents/all-authorised-presentations/hemgenix-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (59.47 KB - PDF)

**First published:**

28/02/2023

[View](/lt/documents/all-authorised-presentations/hemgenix-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (131.76 KB - PDF)

**First published:**

28/02/2023

[View](/hu/documents/all-authorised-presentations/hemgenix-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (57.8 KB - PDF)

**First published:**

28/02/2023

[View](/mt/documents/all-authorised-presentations/hemgenix-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (38.79 KB - PDF)

**First published:**

28/02/2023

[View](/nl/documents/all-authorised-presentations/hemgenix-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (39.91 KB - PDF)

**First published:**

28/02/2023

[View](/no/documents/all-authorised-presentations/hemgenix-epar-all-authorised-presentations_no.pdf)

polski (PL) (59.97 KB - PDF)

**First published:**

28/02/2023

[View](/pl/documents/all-authorised-presentations/hemgenix-epar-all-authorised-presentations_pl.pdf)

português (PT) (39.98 KB - PDF)

**First published:**

28/02/2023

[View](/pt/documents/all-authorised-presentations/hemgenix-epar-all-authorised-presentations_pt.pdf)

română (RO) (48.45 KB - PDF)

**First published:**

28/02/2023

[View](/ro/documents/all-authorised-presentations/hemgenix-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (56.37 KB - PDF)

**First published:**

28/02/2023

[View](/sk/documents/all-authorised-presentations/hemgenix-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (70.58 KB - PDF)

**First published:**

28/02/2023

[View](/sl/documents/all-authorised-presentations/hemgenix-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (35.07 KB - PDF)

**First published:**

28/02/2023

[View](/fi/documents/all-authorised-presentations/hemgenix-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (38.94 KB - PDF)

**First published:**

28/02/2023

[View](/sv/documents/all-authorised-presentations/hemgenix-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Hemgenix Active substance Etranacogene dezaparvovec International non-proprietary name (INN) or common name etranacogene dezaparvovec Therapeutic area (MeSH) Hemophilia B Anatomical therapeutic chemical (ATC) code B02BD

### Pharmacotherapeutic group

Blood coagulation factors

### Therapeutic indication

Treatment of severe and moderately severe Haemophilia B (congenital Factor IX deficiency) in adult patients without a history of Factor IX inhibitors.

## Authorisation details

EMA product number EMEA/H/C/004827

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Advanced therapy

This medicine is classified as an advanced therapy medicinal product (ATMP): a medicine for human use that is based on genes, tissues or cells. It offers groundbreaking new opportunities for the treatment of disease and injury. For more information, see [Advanced therapy medicinal products: Overview](/node/69659) .

Conditional approval

This medicine received a conditional marketing authorisation. This was granted in the interest of public health because the medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. For more information, see [Conditional marketing authorisation](/node/68774) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

PRIME: priority medicine

This medicine was granted entry to the EMA Priority Medicines (PRIME) scheme during its development. PRIME is a scheme launched by EMA to enhance support for the development of medicines that target an unmet medical need. This voluntary scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimise development plans and speed up evaluation so these medicines can reach patients earlier. For more information, see [PRIME: priority medicines](/node/69853) .

Marketing authorisation holder

CSL Behring GmbH

Emil-von-Behring-Straße 76

Opinion adopted 15/12/2022 Marketing authorisation issued 20/02/2023 Revision 6

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Hemgenix : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (174.4 KB - PDF)

**First published:** 13/04/2023

**Last updated:** 15/01/2025

[View](/en/documents/procedural-steps-after/hemgenix-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Hemgenix : EPAR - Orphan Maintenance Assessment Report

Adopted

Reference Number: EMADOC-1700519818-997049

English (EN) (666.89 KB - PDF)

**First published:** 28/02/2023

[View](/en/documents/orphan-maintenance-report/hemgenix-epar-orphan-maintenance-assessment-report_en.pdf)

Hemgenix : EPAR - Public assessment report

Adopted

Reference Number: EMA/46569/2023

English (EN) (2.82 MB - PDF)

**First published:** 28/02/2023

[View](/en/documents/assessment-report/hemgenix-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Hemgenix

Adopted

Reference Number: EMA/CHMP/916178/2022

English (EN) (148.64 KB - PDF)

**First published:** 16/12/2022

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-hemgenix_en.pdf)

#### News on Hemgenix

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 December 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-december-2022) 16/12/2022

[First gene therapy to treat haemophilia B](/en/news/first-gene-therapy-treat-haemophilia-b) 16/12/2022

#### More information on Hemgenix

- [EU/3/18/1999 - orphan designation for treatment of haemophilia B](/en/medicines/human/orphan-designations/eu-3-18-1999)
- [An Observational Post-authorization Long-term Follow-up Study to Characterize the Effectiveness and Safety of HEMGENIX® (Etranacogene Dezaparvovec) in Patients with Hemophilia B (CSL222\\_4001) - post-authorisation study](https://catalogues.ema.europa.eu/study/106067)

**This page was last updated on** 15/01/2025

## Share this page

[Back to top](#main-content)